ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 885

A 2-Week Single-Blind, Randomized, 3-Arm Proof of Concept Study of the Effects of Secukinumab (anti-IL17 mAb), Canakinumab (anti-IL-1 b mAb), or Corticosteroids on Initial Disease Activity Scores in Patients with PMR, Followed By an Open-Label Extension to Assess Safety and Effect Duration

Eric L. Matteson1, Bhaskar Dasgupta2, Wolfgang A. Schmidt3, Carlo Salvarani4, Nagui Gendi5, Mauro Galeazzi6, Sylvie Stitah7, Yue Li8, Marie-Anne Valentin9, Bolan Linghu10 and Stephen J. Oliver7, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Rheumatology, Southend University Hospital, Essex, United Kingdom, 3Rheumatology, Immanuel Krankenhaus, Berlin, Germany, 4Rheumatology Unit, Arcispedale-Santa-Maria-Nuova, Reggio Emilia, Italy, 5Rheumatology, Basildon & Thurroch University Hospitals NHS Trust, Basildon, Essex, United Kingdom, 6Sezione di Reumatologia, Università di Siena, Siena, Italy, 7Translational Medicine, Novartis Pharma AG, Basel, Switzerland, 8IIS, Novartis Pharma AG, Basel, Switzerland, 9Biomarker Development, Novartis Pharma AG, Basel, Switzerland, 10Translational Medicine, Novartis Pharma AG, Cambridge, MA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: clinical trials and polymyalgia rheumatica, IL-1/IL-18, Intervention

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis I

Session Type: Abstract Submissions (ACR)

Background/Purpose To assess the effects of a single dose of secukinumab or canakinumab in patients with new onset, untreated polymyalgia rheumatica (PMR).

Methods In this single-blinded, double-dummy, randomized, active-controlled, parallel-group study, patients with PMR of >1 week duration were randomized 1:1:1 to receive single dose (3 mg/kg/body weight) of either secukinumab or canakinumab, or daily oral prednisone (PRED) at 20 mg a day.  The primary endpoint was efficacy after 2 weeks, assessed by the PMR activity score (PMR-AS components: CRP, morning stiffness, ability to elevate arms; 100 mm VAS assessments for patient pain and physician global). Complete response was defined as >70% reduction in patient global assessment VAS compared with baseline, morning stiffness <30 min, and CRP <1.0 mg/dl. Partial response was defined as >50% reduction in patient global assessment VAS compared with baseline and morning stiffness <60 min. Patients treated with biologics failing to achieve criteria for either complete or partial response by Day 15 initiated treatment with PRED 20 mg/day. All patients receiving PRED underwent a scheduled taper after 2 weeks treatment. Patients were followed up to 154 days for safety and duration of treatment effects. Serum levels of IL-6 and VEGF were measured by ELISA.

Results 16 patients (11 females) were randomized (secukinumab, n=6, mean baseline PMR-AS 46.6; canakinumab, n=5, mean PMR-AS 54.3; PRED n=5, mean baseline PMR-AS 37.5). The primary endpoint was assessed in 13 patients (secukinumab, 6; canakinumab, 3; PRED, 4). PMR-AS reductions from baseline were seen in all patients at day 15: secukinumab =52%; canakinumab =65%; PRED 92%. By Day 15 no biologic-treated patients achieved complete response and only 1 patient in each biologic group achieved a partial response, whereas 1 patient in the PRED arm had complete response and 3 patients had partial responses. CRP reductions were most rapid in the PRED group and more consistent in patients treated with either PRED or secukinumab. In patients treated with PRED, rapid reductions were observed in mean VAS for physician global assessment and patients’ assessment of pain compared to only moderate or minimal effects in the secukinumab and canakinumab groups, respectively. PRED induced a rapid and consistent decrease in IL-6 while no consistent effects were noted in patients treated with biologics. Secukinumab induced rapid and consistent decreases in VEGF levels that were not observed in the other two groups. Patients in secukinumab (n=4) and canakinumab (n=3) groups who required switch to PRED with subsequent taper had a 40% and 35% lower monthly average steroid use, respectively, compared to the PRED group (n=4) that had not been exposed to a biologic. All three study treatments were well-tolerated without SAEs or increased infections noted.

Conclusion In this study PMR-AS reduced more rapidly by Day 15 in prednisone-treated patients than in patients receiving secukinumab or canakinumab. Patients receiving biologics followed by prednisone had overall lower cumulative steroid doses.  The therapeutic effects of secukinumab and canakinumab in PMR remains uncertain and deserves further study.


Disclosure:

E. L. Matteson,

Novartis Pharma AG,

2;

B. Dasgupta,

Novartis Pharma AG,

2;

W. A. Schmidt,

Novartis Pharma AG,

2,

Mundipharma,

2;

C. Salvarani,

Novartis Pharma AG,

2;

N. Gendi,

Novartis Pharma AG,

2,

Roche Pharma AG,

2,

UCB Pharma,

2;

M. Galeazzi,
None;

S. Stitah,

Novartis Pharma AG,

3;

Y. Li,

Novartis Pharma AG,

3;

M. A. Valentin,

Novartis Pharma AG,

3;

B. Linghu,

Novartis Pharma AG,

3;

S. J. Oliver,

Novartis Pharma AG,

1,

Novartis Pharma AG,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-2-week-single-blind-randomized-3-arm-proof-of-concept-study-of-the-effects-of-secukinumab-anti-il17-mab-canakinumab-anti-il-1-b-mab-or-corticosteroids-on-initial-disease-activity-scores-in-p/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology